Biotechnology shares rose, gaining back value lost following the US terror attacks as investors grew confident that the group may escape some of the impact of a recession and rushed in to pick up small-cap bargains.
Most of the biggest percentage gainers were small companies, including Biotransplant Inc, which rose US$1.30, or 30 percent, to US$5.50 and Ariad Pharmaceuticals Inc, which rose US$0.49, or 25 percent, to US$2.45. Texas Biotech Corp rose US$0.65, or 13 percent, to US$5.65.
Now, some investors say third quarter product sales won't be affected by the economic slowdown and that biotechnology shares fell too far after the Sept. 11 attacks. In the first trading week after the attacks, the NASDAQ Biotechnology Index fell 17 percent, adding to a 23 percent decline since Jan. 1.
"Nothing has really changed as far as the fundamentals of the sector go," said Alidad Mireskandari, co-manager of the Orbitex Health & Biotechnology Fund. "When you look at the sector, you have to say it was severely oversold." Still, shares of large, profitable biotechnology companies, such as Amgen Inc. and Biogen Inc, fell as small companies dominated the rally, a turnaround that surprised investors.
"We thought it would be a large cap lead out of" the recent decline in the market, said Greg Aurand, co-manager of the Orbitex Health & Biotechnology Fund, whose largest holdings include Amgen Inc and Idec Pharmaceuticals Corp.
Shares of Amgen., the world's largest biotechnology company, fell US$0.68 to US$58.77. Biogen Inc, maker of the top-selling multiple sclerosis treatment Avonex fell US$1.38 to US$55.58.
Investor Stephen Flaks, manager of Flaks Partners LP, a hedge fund that invests in biotechnology companies, said shares of small companies with promising pipelines and technologies were "compelling" buys.
Flaks said he was taking advantage of the downturn in the market to load up on shares of Texas Biotech, which markets a heart drug with SmithKline Beecham Plc, and Neose Technologies Inc, which develops technologies for synthesizing enzymes in drugs.
"I was actually surprised after the disaster that the biotechs went down as much as they did," Flaks said. "Biotech is not a safe haven like drug stocks, but on the other hand you're not going to have the earnings recession as in other industries."
Flaks is also buying Immunex Corp, whose shares have tumbled 53 percent this year because the company has been unable to make enough of its Enbrel rheumatoid arthritis drug to meet demand.
Immunex is expected to complete a new plant in mid-2002, resolving the manufacturing constraints.
"I think it's got a lot of room on the upside," Flaks said.
Shares of Immunex moved up US$0.36 to US$18.68.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure